Role of estrogen in suppressing autoimmunity in coxsackievirus B3-induced myocarditis

Future Virology

Volumn 5, Issue 3, 2010, Pages 273-286

  Huber, S A ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Autoimmunity; Estrogen; Picornavirus; Sex differences; T regulatory cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DECAY ACCELERATING FACTOR; EPITOPE; ESTROGEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONAL ANERGY; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; PROTEIN METHYLATION; REGULATORY T LYMPHOCYTE; REVIEW; RNA VIRUS; SEX DIFFERENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS MYOCARDITIS; X CHROMOSOME INACTIVATION;

COXSACKIEVIRUS; PICORNAVIRIDAE; RNA VIRUSES;

EID: 77952248912     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.19     Document Type: Review

References (182)

1. Munz C, Lunemann JD, Getts MT, Miller SD: Antiviral immune responses: triggers of or triggered by autoimmunity? Nat. Rev. Immunol. 9(4), 246-258 (2009).
2. Goldberg E, Krause I: Infection and Type 1 diabetes mellitus - a two edged sword? Autoimmun. Rev. 8(8), 682-686 (2009).
3. Root-Bernstein R, Vonck J, Podufaly A: Antigenic complementarity between coxsackie virus and streptococcus in the induction of rheumatic heart disease and autoimmune myocarditis. Autoimmunity 42(1), 1-16 (2009).
4. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR: From infection to autoimmunity. J. Autoimmun. 16(3), 175-186 (2001).
5. Pohl D: Epstein-Barr virus and multiple sclerosis. J. Neurol. Sci. 286(1-2), 62-64 (2009).
6. Doria A, Canova M, Tonon M et al.: Infections as triggers and complications of systemic lupus erythematosus. Autoimmun. Rev. 8(1), 24-28 (2008).
7. Horwitz M, Sarvetnick N: Viruses, host responses, and autoimmunity. Immunol. Rev. 169, 241-253 (1999).
8. Savino W: The thymus is a common target organ in infectious diseases. PLoS Pathog. 2(6), e62 (2006).
9. Wang D, Muller N, McPherson KG, Reichardt HM: Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J. Immunol. 176(3), 1695-1702 (2006).
10. Matteucci D, Toniolo A, Conaldi PG, Basolo F, Gori Z, Bendinelli M: Systemic lymphoid atrophy in coxsackievirus B3-infected mice: effects of virus and immunopotentiating agents. J. Infect. Dis. 151(6), 1100-1108 (1985).
11. D'souza WN, Lefrancois L: Frontline: an in-depth evaluation of the production of IL-2 by antigen-specific CD8 T cells in vivo. Eur. J. Immunol. 34(11), 2977-2985 (2004).
12. Saibil SD, Deenick EK, Ohashi PS: The sound of silence: modulating anergy in T lymphocytes. Curr. Opin. Immunol. 19(6), 658-664 (2007).
13. Adler HS, Steinbrink K: MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle 7(2), 169-170 (2008).
14. Wells AD: New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J. Immunol. 182(12), 7331-7341 (2009).
15. Boussiotis VA, Freeman GJ, Taylor PA et al.: P27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6(3), 290-297 (2000).
16. Wells AD, Walsh MC, Sankaran D, Turka LA: T cell effector function and anergy avoidance are quantitatively linked to cell division. J. Immunol. 165(5), 2432-2443 (2000).
17. Li L, Iwamoto Y, Berezovskaya A, Boussiotis VA: A pathway regulated by cell cycle inhibitor p27kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat. Immunol. 7(11), 1157-1165 (2006).
18. Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD: Anergic T cells are metabolically anergic. J. Immunol. 183(10), 6095-6101 (2009).
19. Riley JL: PD-1 signaling in primary T cells. Immunol. Rev. 229(1), 114-125 (2009).
20. Chikuma S, Terawaki S, Hayashi T et al.: PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J. Immunol. 182(11), 6682-6689 (2009).
21. Grabie N, Gotsman I, Dacosta R et al.: Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116(18), 2062-2071 (2007).
22. Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR: Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol. 181(4), 2513-2521 (2008).
23. Seko Y, Yagita H, Okumura K, Azuma M, Nagai R: Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. Cardiovasc. Res. 75(1), 158-167 (2007).
24. Si X, Luo H, Morgan A et al.: Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release. J. Virol. 79(22), 13875-13881 (2005).
25. Luo H, Yanagawa B, Zhang J et al.: Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J. Virol. 76(7), 3365-3373 (2002).
26. Triantafilou K, Triantafilou M: Lipid-raft-dependent coxsackievirus B4 internalization and rapid targeting to the golgi. Virology 326(1), 6-19 (2004).
27. Triantafilou K, Triantafilou M: Lipid raft microdomains: key sites for coxsackievirus A9 infectious cycle. Virology 317(1), 128-135 (2003).
28. Schwartz RH: T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
29. Huber S, Polgar J, Schultheiss P, Schwimmbeck P: Augmentation of pathogenesis of coxsackievirus B3 infections in mice by exogenous administration of interleukin-1 and interleukin-2. J. Virol. 68, 195-206 (1994).
30. Suzuki M, Konya C, Goronzy JJ, Weyand CM: Inhibitory CD8+ T cells in autoimmune disease. Hum. Immunol. 69(11), 781-789 (2008).
31. Mellanby RJ, Thomas DC, Lamb J: Role of regulatory T-cells in autoimmunity. Clin. Sci. (Lond.) 116(8), 639-649 (2009).
32. Wing K, Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11(1), 7-13 (2009).
33. Zheng Y, Rudensky AY: FoxP3 in control of the regulatory T cell lineage. Nat. Immunol. 8(5), 457-462 (2007).
34. Thornton AM, Piccirillo CA, Shevach EM: Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur. J. Immunol. 34(2), 366-376 (2004).
35. Rudensky AY, Gavin M, Zheng Y: FOXP3 and NFAT: partners in tolerance. Cell 126(2), 253-256 (2006).
36. Torgerson TR, Genin A, Chen C et al.: FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression. J. Immunol. 183(2), 907-915 (2009).
37. Sakaguchi S: Naturally arising FOXP3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4), 345-352 (2005).
38. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell 133(5), 775-787 (2008).
39. Weaver CT, Hatton RD: Interplay between the Th17 and Treg cell lineages: a (co-) evolutionary perspective. Nat. Rev. Immunol. 9(12), 883-889 (2009).
40. Peck A, Mellins ED: Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin. Immunol. 132(3), 295-304 (2009).
41. Wang RF, Miyahara Y, Wang HY: Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27(2), 181-189 (2008).
42. Crome SQ, Wang AY, Levings MK: Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 159(2), 109-119 (2009).
43. Oida T, Xu L, Weiner HL, Kitani A, Strober W: TGF-b-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J. Immunol. 177(4), 2331-2339 (2006).
44. Frisancho-Kiss S, Nyland JF, Davis SE et al.: Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J. Immunol. 176(11), 6411-6415 (2006).
45. Huber SA, Feldman AM, Sartini D: Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-a transgenic mice. Circ. Res. 99(10), 1109-1116 (2006).
46. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S: A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the woodruff variant of coxsackievirus B3. J. Virol. 70(11), 7811-7818 (1996).
47. Richer MJ, Straka N, Fang D, Shanina I, Horwitz MS: Regulatory T-cells protect from Type 1 diabetes after induction by coxsackievirus infection in the context of transforming growth factor-b. Diabetes 57(5), 1302-1311 (2008).
48. Cihakova D, Barin JG, Afanasyeva M et al.: Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am. J. Pathol. 172(5), 1195-1208 (2008).
49. Taylor BC, Zaph C, Troy AE et al.: TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J. Exp. Med. 206(3), 655-667 (2009).
50. Majlessi L, Lo-Man R, Leclerc C: Regulatory B and T cells in infections. Microbes Infect. 10(9), 1030-1035 (2008).
51. Woodruff JC, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of coxsackievirus B3 heart disease. J. Immunol. 113, 1726-1734 (1974).
52. Juleff N, Windsor M, Lefevre EA et al.: Foot-and-mouth disease virus can induce a specific and rapid CD4+ T-cell-independent neutralizing and isotype class-switched antibody response in naive cattle. J. Virol. 83(8), 3626-3636 (2009).
53. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW: MDA5 and MAVS mediate type I interferon responses to coxsackie B virus. J. Virol. 84(1), 254-260 (2010)
54. Zaragoza C, Ocampo C, Saura M et al.: The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis. Proc. Natl Acad. Sci. USA 95(5), 2469-2474 (1998).
55. Fujinami RS, Oldstone MB: Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230(4729), 1043-1045 (1985).
56. Fujinami RS, Oldstone MB: Molecular mimicry as a mechanism for virus-induced autoimmunity. Immunol. Res. 8(1), 3-15 (1989).
57. Rose NR, Mackay IR: Molecular mimicry: a critical look at exemplary instances in human diseases. Cell Mol. Life Sci. 57(4), 542-551 (2000).
58. Benoist C, Mathis D: Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2(9), 797-801 (2001).
59. Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AG: Cross-reaction between antibodies to the major epitope of RO60 KD autoantigen and a homologous peptide of coxsackie virus 2B protein. Clin. Exp. Immunol. 141(1), 148-154 (2005).
60. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MB: Molecular mimicry and Myasthenia gravis. An autoantigenic site of the acetylcholine receptor a-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J. Clin. Invest. 84(4), 1174-1180 (1989).
61. Hiemstra HS, Schloot NC, Van Veelen PA et al.: Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc. Natl Acad. Sci. USA 98(7), 3988-3991 (2001).
62. Cunningham M, Hall N, Krisher K, Spanier A: A study of anti-group a streptococcal monoclonal antibodies crossreactive with myosin. J. Immunol. 136, 293-298 (1986).
63. Wucherpfennig K, Strominger J: Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
64. Lonnrot M, Hyoty H, Knip M et al.: Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of coxsackievirus B4. Childhood diabetes in Finland study group. Clin. Exp. Immunol. 104(3), 398-405 (1996).
65. Triantafyllopoulou A, Moutsopoulos HM: Autoimmunity and coxsackievirus infection in primary Sjogren's syndrome. Ann. NY Acad. Sci. 1050, 389-396 (2005).
66. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM: Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum. 50(9), 2897-2902 (2004).
67. Youinou P, Pers JO, Saraux A, Pennec YL: Viruses contribute to the development of Sjogren's syndrome. Clin. Exp. Immunol. 141(1), 19-20 (2005).
68. Elfaitouri A, Berg AK, Frisk G, Yin H, Tuvemo T, Blomberg J: Recent enterovirus infection in Type 1 diabetes: evidence with a novel IgM method. J. Med. Virol. 79(12), 1861-1867 (2007).
69. Maclaren NK, Alkinson MA: Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Mol. Med. Today 3(2), 76-83 (1997).
70. Vreugdenhil GR, Batstra MR, Aanstoot HJ, Melchers WJ, Galama JM: Analysis of antibody responses against coxsackie virus B4 protein 2C and the diabetes autoantigen GAD(65). J. Med. Virol. 59(2), 256-261 (1999).
71. Maisch B, Bauer E, Cirsi M, Kocksiek K: Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Circulation 87(Suppl. 5), IV49-IV65 (1993).
72. Maclaren N, Alkinson M: Insulin-dependent diabetes mellitus: the hypthesis of molecular mimicry between islet cell antigens and microorganisms. Mol. Med. Today 3, 76-83 (1997).
73. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER: Binding of immunogenic peptides to IA histocompatibility molecules. Nature 317(6035), 359-361 (1985).
74. Evavold B, Sloan-Lancaster J, Wilson K, Rothbard J, Allen P: Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity 2, 655-663 (1995).
75. Sloan-Lancaster J, Allen PM: Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14, 1-27 (1996).
76. Sloan-Lancaster J, Evavold BD, Allen PM: Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363(6425), 156-159 (1993).
77. Kersh GJ, Allen PM: Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 184(4), 1259-1268 (1996).
78. Lanzavecchia A: How can cryptic epitopes trigger autoimmunity? J. Exp. Med. 181(6), 1945-1948 (1995).
79. Luo H, Zhang J, Dastvan F et al.: Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J. Virol. 77(1), 1-9 (2003).
80. Vidard L, Rock KL, Benacerraf B: Heterogeneity in antigen processing by different types of antigen-presenting cells. Effect of cell culture on antigen processing ability. J. Immunol. 149(6), 1905-1911 (1992).
81. Gresser O, Weber E, Hellwig A, Riese S, Regnier-Vigouroux A: Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S. Eur. J. Immunol. 31(6), 1813-1824 (2001).
82. Salemi S, Caporossi AP, Boffa L, Longobardi MG, Barnaba V: HIVGP120 activates autoreactive CD4-specific T cell responses by unveiling of hidden CD4 peptides during processing. J. Exp. Med. 181(6), 2253-2257 (1995).
83. Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P: Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J. Virol. 67(12), 7383-7393 (1993).
84. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C: Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181(6), 1957-1963 (1995).
85. Driessen C, Lennon-Dumenil AM, Ploegh HL: Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fcg receptors. Eur. J. Immunol. 31(5), 1592-1601 (2001).
86. Gauntt C, Sakkinen P, Rose N, Huber S: Picornaviruses: immunopathology and autoimmunity. In: Effects of Microbes on the Immune System. Cunningham M, Fujinami R (Eds). Lippincott-Raven Publishers, PA, USA 313-329 (2000).
87. Badorff C, Lee GH, Lamphear BJ et al.: Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5(3), 320-326 (1999).
88. O'Hagan DT, Valiante NM: Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2(9), 727-735 (2003).
89. Marrack P, Mckee AS, Munks MW: Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9(4), 287-293 (2009).
90. Allison AC: Immunological adjuvants and their modes of action. Arch. Immunol. Ther. Exp. (Warsz.) 45(2-3), 141-147 (1997).
91. Abreu MT, Arditi M: Innate immunity and Toll-like receptors: clinical implications of basic science research. J. Pediatr. 144(4), 421-429 (2004).
92. Means TK, Golenbock DT, Fenton MJ: The biology of Toll-like receptors. Cytokine Growth Factor Rev. 11(3), 219-232 (2000).
93. Netea MG, Van Der Meer JW, Kullberg BJ: Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 12(11), 484-488 (2004).
94. O'Neill LA: TLRS: Professor Mechnikov, sit on your hat. Trends Immunol. 25(12), 687-693 (2004).
95. Lauw FN, Caffrey DR, Golenbock DT: Of mice and man: TLR11 (finally) finds profilin. Trends Immunol. 26(10), 509-511 (2005).
96. Hasan U, Chaffois C, Gaillard C et al.: Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MYD88. J. Immunol. 174(5), 2942-2950 (2005).
97. Pulendran B: Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174(5), 2457-2465 (2005).
98. Netea MG, Van Der Meer JW, Sutmuller RP, Adema GJ, Kullberg BJ: From the TH1/ TH2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob. Agents Chemother. 49(10), 3991-3996 (2005).
99. Liew FY, Komai-Koma M, Xu D: A toll for T cell costimulation. Ann. Rheum. Dis. 63(Suppl. 2), II76-II78 (2004).
100. Dong Z, Wei H, Sun R, Tian Z: The roles of innate immune cells in liver injury and regeneration. Cell Mol. Immunol. 4(4), 241-252 (2007).
101. Li Y, Heuser JS, Kosanke SD, Hemric M, Cunningham MW: Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cells. Am. J. Pathol. 167(1), 5-15 (2005).
102. Wang Y, Afanasyeva M, Hill SL, Kaya Z, Rose NR: Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J. Am. Coll. Cardiol. 36(6), 1992-1999 (2000).
103. Taneja V, Hansen J, Smart M, Griffiths M, Luthra H, David C: Expression of H-2E molecule mediates protection to collagen induced arthritis in HLA-DQ8 transgenic mice: role of cytokines. Int. Immunol. 9, 1213-1219 (1997).
104. Rose NR: The adjuvant effect in infection and autoimmunity. Clin. Rev. Allergy Immunol. 34(3), 279-282 (2008).
105. Frisancho-Kiss S, Davis SE, Nyland JF et al.: Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J. Immunol. 178(11), 6710-6714 (2007).
106. Triantafilou K, Triantafilou M: Coxsackievirus B4-induced cytokine production in pancreatic cells is mediated through Toll-like receptor 4. J. Virol. 78(20), 11313-11320 (2004).
107. Avalos AM, Busconi L, Marshak-Rothstein A: Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 43(1), 76-83 (2009).
108. Drexler SK, Foxwell BM: The role of Toll-like receptors in chronic inflammation. Int. J. Biochem. Cell Biol. 42(4), 506-518 (2009).
109. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Van Den Brand BT, Van De Loo FA, Van Den Berg WB: Local interleukin-1-driven joint pathology is dependent on Toll-like receptor 4 activation. Am. J. Pathol. 175(5), 2004-2013 (2009).
110. Zhang P, Cox CJ, Alvarez KM, Cunningham MW: Cutting edge: cardiac myosin activates innate immune responses through TLRs. J. Immunol. 183(1), 27-31 (2009).
111. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR: Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kB dependent inflammatory response. Cardiovasc. Res. 72(3), 384-393 (2006).
112. Zhu X, Bagchi A, Zhao H et al.: Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit. Care Med. 35(3), 886-892 (2007).
113. Xu J, Yang Y, Wang C, Jiang B: Rotavirus and coxsackievirus infection activated different profiles of Toll-like receptors and chemokines in intestinal epithelial cells. Inflamm. Res. 58(9), 585-592 (2009).
114. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ: Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol. 27(8), 387-393 (2006).
115. Sakaguchi S, Setoguchi R, Yagi H, Nomura T: Naturally arising FOXP3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr. Top. Microbiol. Immunol. 305, 51-66 (2006). (Pubitemid 47400264)
116. Lehner T: Special regulatory T cell review: the resurgence of the concept of contrasuppression in immunoregulation. Immunology 123(1), 40-44 (2008).
117. Harnaha J, Machen J, Wright M et al.: Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 55(1), 158-170 (2006).
118. Jonuleit H, Knop J, Enk AH: Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch. Dermatol. Res. 289(1), 1-8 (1996).
119. Stoop JN, Woltman AM, Biesta PJ et al.: Tumor necrosis factor a inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. Hepatology 46(3), 699-705 (2007).
120. Liu G, Zhang L, Zhao Y: Modulation of immune responses through direct activation of Toll-like receptors to T cells. Clin. Exp. Immunol. (2010) (Epub ahead of print).
121. Klein Sl, Huber SA: Sex differences in susceptibility to viral infection. In: Sex Hormones and Immunity to Infection. Klein Slar CW (Ed.). Springer Verlag, Berlin, Germany (2010).
122. Smithson G, Couse J, Lubahn D, Korach K, Kincade P: The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphocytes. J. Immunol. 161, 27-34 (1998).
123. Islander U, Erlandsson MC, Hasseus B et al.: Influence of oestrogen receptor a and b on the immune system in aged female mice. Immunology 110(1), 149-157 (2003).
124. Paharkova-Vatchkova V, Maldonado R, Kovats S: Estrogen preferentially promotes the differentiation of CD11C+ CD11B (intermediate) dendritic cells from bone marrow precursors. J. Immunol. 172(3), 1426-1436 (2004).
125. Ito A, Bebo BF Jr, Matejuk A et al.: Estrogen treatment down-regulates TNF-a production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J. Immunol. 167(1), 542-552 (2001).
126. Li J, McMurray RW: Effects of estrogen receptor subtype-selective agonists on immune functions in ovariectomized mice. Int. Immunopharmacol. 6(9), 1413-1423 (2006).
127. Lambert KC, Curran EM, Judy BM, Milligan GN, Lubahn DB, Estes DM: Estrogen receptor a (ERa) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17b-estradiol acts through ERa to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation. J. Immunol. 175(9), 5716-5723 (2005).
128. Karpuzoglu-Sahin E, Hissong BD, Ansar Ahmed S: Interferon-g levels are upregulated by 17-b-estradiol and diethylstilbestrol. J. Reprod. Immunol. 52(1-2), 113-127 (2001).
129. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B: Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 109(12), 1625-1633 (2002).
130. Polanczyk MJ, Hopke C, Huan J, Vandenbark AA, Offner H: Enhanced FOXP3 expression and TReg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol. 170(1-2), 85-92 (2005).
131. Polanczyk MJ, Jones RE, Subramanian S et al.: T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am. J. Pathol. 165(6), 2069-2077 (2004).
132. Tai P, Wang J, Jin H et al.: Induction of regulatory T cells by physiological level estrogen. J. Cell. Physiol. 214(2), 456-464 (2008).
133. Liu HY, Buenafe AC, Matejuk A et al.: Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70(2), 238-248 (2002).
134. Schwartz J, Sartini D, Huber S: Myocarditis susceptibility in female mice depends upon ovarian cycle phase at infection. Virology 330(1), 16-23 (2004).
135. Matthews J, Gustafsson JA: Estrogen signaling: a subtle balance between ER and ER b. Mol. Interv. 3(5), 281-292 (2003).
136. Scariano JK, Emery-Cohen AJ, Pickett GG, Morgan M, Simons PC, Alba F: Estrogen receptors a (ESR1) and b (ESR2) are expressed in circulating human lymphocytes. J. Recept. Signal Transduct. Res. 28(3), 285-293 (2008).
137. Carreras E, Turner S, Paharkova-Vatchkova V, Mao A, Dascher C, Kovats S: Estradiol acts directly on bone marrow myeloid progenitors to differentially regulate GM-CSF or FLT3 ligand-mediated dendritic cell differentiation. J. Immunol. 180(2), 727-738 (2008).
138. Douin-Echinard V, Laffont S, Seillet C et al.: Estrogen receptor a, but not b, is required for optimal dendritic cell differentiation and [corrected] CD40-induced cytokine production. J. Immunol. 180(6), 3661-3669 (2008).
139. Tsutsumi S, Zhang X, Takata K et al.: Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2. J. Endocrinol. 199(2), 267-273 (2008).
140. Klinge CM: Estrogenic control of mitochondrial function and biogenesis. J. Cell. Biochem. 105(6), 1342-1351 (2008).
141. Kubarek L, Jagodzinski PP: Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 b-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in ishikawa endometrial adenocarcinoma cells. FEBS lett. 581(7), 1441-1448 (2007).
142. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins avb3 and avb5 promote adenovirus internalization but not virus attachment. Cell 73(2), 309-319 (1993).
143. Roivainen M, Piirainen L, Hovi T et al.: Entry of coxsackievirus A9 into host cells: specific interactions with avb 3 integrin, the vitronectin receptor. Virology 203(2), 357-365 (1994).
144. Li CF, Ross FP, Cao X, Teitelbaum SL: Estrogen enhances avb3 integrin expression by avian osteoclast precursors via stabilization of b3 integrin mRNA. Mol. Endocrinol. 9(7), 805-813 (1995).
145. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER: b3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc. Natl Acad. Sci. USA 95(12), 7074-7079 (1998).
146. Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW: Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J. Infect. Dis. 175(3), 697-700 (1997).
147. Goodfellow IG, Evans DJ, Blom AM et al.: Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J. Virol. 79(18), 12016-12024 (2005).
148. Shafren D: Viral cell entry induced by cross-linked decay-accelerating factor. J. Virol. 72, 9407-9412 (1998).
149. Selinka HC, Wolde A, Sauter M, Kandolf R, Klingel K: Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism. Med. Microbiol. Immunol. 193(2-3), 127-131 (2004).
150. Pasch A, Kupper JH, Wolde A, Kandolf R, Selinka HC: Comparative analysis of virus-host cell interactions of haemagglutinating and non-haemagglutinating strains of coxsackievirus B3. J. Gen. Virol. 80(Pt 12), 3153-3158 (1999).
151. Yanagawa B, Spiller OB, Choy J et al.: Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab. Invest. 83(1), 75-85 (2003).
152. Yanagawa B, Spiller OB, Proctor DG et al.: Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus B3-mediated pancreatitis and myocarditis in mice. J. Infect. Dis. 189(8), 1431-1439 (2004).
153. Huber S, Song WC, Sartini D: Decay-accelerating factor (CD55) promotes CD1D expression and Vg4+ T-cell activation in coxsackievirus B3-induced myocarditis. Viral Immunol. 19(2), 156-166 (2006).
154. Song WC, Deng C, Raszmann K et al.: Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J. Immunol. 157(9), 4166-4172 (1996).
155. Lyden D, Olszewski J, Feran M, Job L, Huber S: Coxsackievirus B3-induced myocarditis. Effects of sex steroids on viremia and infectivity of cardiocytes. Am. J. Pathol. 126, 432-438 (1987).
156. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC: Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc. Natl Acad. Sci. USA 96(2), 628-633 (1999).
157. Liu J, Miwa T, Hilliard B et al.: The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201(4), 567-577 (2005).
158. Miwa T, Maldonado MA, Zhou L et al.: Deletion of decay-accelerating factor (cd55) exacerbates autoimmune disease development in MRL/LPR mice. Am. J. Pathol. 161(3), 1077-1086 (2002).
159. Vincent T, Pettersson RF, Crystal RG, Leopold PL: Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells. J. Virol. 78(15), 8047-8058 (2004).
160. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C: JAM-1 is a ligand of the b(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat. Immunol. 3(2), 151-158 (2002).
161. Lisewski U, Shi Y, Wrackmeyer U et al.: The tight junction protein car regulates cardiac conduction and cell-cell communication. J. Exp. Med. 205(10), 2369-2379 (2008).
162. Carson SD, Chapman NM: Coxsackievirus and adenovirus receptor (CAR) binds immunoglobulins. Biochemistry 40(48), 14324-14329 (2001).
163. Haynes M, Huber S, Craighead J: Helper-inducer T lymphocytes mediate diabetes in EMC-infected BALB/CBYJ mice. Diabetes 36, 877-881 (1987).
164. Miller S, Vanderlugt C, Begolka W et al.: Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3, 1133-1136 (1997).
165. Olson JK, Ercolini AM, Miller SD: A virus-induced molecular mimicry model of multiple sclerosis. Curr. Top. Microbiol. Immunol. 296, 39-53 (2005).
166. Huber S: T cells in coxsackievirus induced myocarditis. Viral Immunol. 17, 152-164 (2004).
167. Huber S, Lodge P: Coxsackievirus B3 myocarditis in BALB/C mice: evidence for autoimmunity to myocyte antigens. Am. J. Path. 116, 21 (1984).
168. Huber SA, Sartini D, Exley M: Vg4+ T cells promote autoimmune CD8+ cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4+ Th1 cells. J. Virol. 76(21), 10785-10790 (2002).
169. Huber SA, Gauntt CJ: Antigenic mimicry between self and coxsackievirus proteins leads to both humoral and cellular autoimmunity to heart proteins. In: Molecular Mimicry, Microbes and Autoimmunity. Cunningham MW, Fujinami RS (Eds). ASM Press, East Norwalk, CT, USA, 57-68. (1999)
170. Huber S, Job L, Auld K: Influence of sex hormones on coxsackie B3 virus infection in BALB/C mice. Cell. Immunol. 67(173-189), 173-179 (1982).
171. Huber S, Kupperman J, Newell M: Hormonal regulation of CD4+ T-cell responses in coxsackievirus B3-induced myocarditis in mice. J. Virol. 73, 4689-4695 (1999).
172. Huber S, Pfaeffle B: Differential Th1 and Th2 cell responses in male and female BALB/C mice infected with coxsackievirus group B type 3. J. Virol. 68, 5126-5132 (1994).
173. Huber SA, Pfaeffle B: Differential Th1 and Th2 cell responses in male and female BALB/C mice infected with coxsackievirus group B type 3. J. Virol. 68(8), 5126-5132 (1994).
174. Huber SA: Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells. Virology 378(2), 292-298 (2008).
175. Offner H, Polanczyk M: A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann. NY Acad. Sci. 1089, 343-372 (2006).
176. Ziegler SF: FOXP3: of mice and men. Annu. Rev. Immunol. 24, 209-226 (2006).
177. Wutz A: Xist function: bridging chromatin and stem cells. Trends Genet. 23(9), 457-464 (2007).
178. Shapiro LJ, Mohandas T, Weiss R, Romeo G: Non-inactivation of an X-chromosome locus in man. Science 204(4398), 1224-1226 (1979).
179. Disteche CM, Filippova GN, Tsuchiya KD: Escape from X inactivation. Cytogenet. Genome Res. 99(1-4), 36-43 (2002).
180. Lal G, Bromberg JS: Epigenetic mechanisms of regulation of FOXP3 expression. Blood 114(18), 3727-3735 (2009).
181. Salem ML: Estrogen, a double-edged sword: Modulation of Th1-and Th2-mediated inflammations by differential regulation of Th1/Th2 cytokine production. Curr. Drug Targets Inflamm. Allergy 3(1), 97-104 (2004).
182. Ray P, Ghosh SK, Zhang DH, Ray A: Repression of interleukin-6 gene expression by 17 b-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kB by the estrogen receptor. FEBS letters 409(1), 79-85 (1997).